320 related articles for article (PubMed ID: 28306514)
1. PARK2 Depletion Connects Energy and Oxidative Stress to PI3K/Akt Activation via PTEN S-Nitrosylation.
Gupta A; Anjomani-Virmouni S; Koundouros N; Dimitriadi M; Choo-Wing R; Valle A; Zheng Y; Chiu YH; Agnihotri S; Zadeh G; Asara JM; Anastasiou D; Arends MJ; Cantley LC; Poulogiannis G
Mol Cell; 2017 Mar; 65(6):999-1013.e7. PubMed ID: 28306514
[TBL] [Abstract][Full Text] [Related]
2. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
[TBL] [Abstract][Full Text] [Related]
3. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.
Carver BS; Chapinski C; Wongvipat J; Hieronymus H; Chen Y; Chandarlapaty S; Arora VK; Le C; Koutcher J; Scher H; Scardino PT; Rosen N; Sawyers CL
Cancer Cell; 2011 May; 19(5):575-86. PubMed ID: 21575859
[TBL] [Abstract][Full Text] [Related]
4. PTEN regulates angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells.
Ma J; Sawai H; Ochi N; Matsuo Y; Xu D; Yasuda A; Takahashi H; Wakasugi T; Takeyama H
Mol Cell Biochem; 2009 Nov; 331(1-2):161-71. PubMed ID: 19437103
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.
Yi YW; Kang HJ; Kim HJ; Hwang JS; Wang A; Bae I
Mol Carcinog; 2013 Sep; 52(9):667-75. PubMed ID: 22488590
[TBL] [Abstract][Full Text] [Related]
6. On-off system for PI3-kinase-Akt signaling through S-nitrosylation of phosphatase with sequence homology to tensin (PTEN).
Numajiri N; Takasawa K; Nishiya T; Tanaka H; Ohno K; Hayakawa W; Asada M; Matsuda H; Azumi K; Kamata H; Nakamura T; Hara H; Minami M; Lipton SA; Uehara T
Proc Natl Acad Sci U S A; 2011 Jun; 108(25):10349-54. PubMed ID: 21646525
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
8. Administration of telmisartan reduced systolic blood pressure and oxidative stress probably through the activation of PI3K/Akt/eNOS pathway and NO release in spontaneously hypertensive rats.
Xu L; Liu Y
Physiol Res; 2013; 62(4):351-9. PubMed ID: 23590610
[TBL] [Abstract][Full Text] [Related]
9. AKT1-CREB stimulation of PDGFRα expression is pivotal for PTEN deficient tumor development.
Wan X; Zhou M; Huang F; Zhao N; Chen X; Wu Y; Zhu W; Ni Z; Jin F; Wang Y; Hu Z; Chen X; Ren M; Zhang H; Zha X
Cell Death Dis; 2021 Feb; 12(2):172. PubMed ID: 33568640
[TBL] [Abstract][Full Text] [Related]
10. E3 ubiquitin ligase RNF126 affects bladder cancer progression through regulation of PTEN stability.
Xu H; Ju L; Xiong Y; Yu M; Zhou F; Qian K; Wang G; Xiao Y; Wang X
Cell Death Dis; 2021 Mar; 12(3):239. PubMed ID: 33664240
[TBL] [Abstract][Full Text] [Related]
11. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
[TBL] [Abstract][Full Text] [Related]
12. ARL4C stabilized by AKT/mTOR pathway promotes the invasion of PTEN-deficient primary human glioblastoma.
Chen Q; Weng HY; Tang XP; Lin Y; Yuan Y; Li Q; Tang Z; Wu HB; Yang S; Li Y; Zhao XL; Fu WJ; Niu Q; Feng H; Zhang X; Wang Y; Bian XW; Yao XH
J Pathol; 2019 Feb; 247(2):266-278. PubMed ID: 30357833
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
14. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
Tan M; Xu J; Siddiqui J; Feng F; Sun Y
Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
[TBL] [Abstract][Full Text] [Related]
15. Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models.
Xu S; Li S; Guo Z; Luo J; Ellis MJ; Ma CX
Mol Cancer Ther; 2013 Aug; 12(8):1665-75. PubMed ID: 23689832
[TBL] [Abstract][Full Text] [Related]
16. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
[TBL] [Abstract][Full Text] [Related]
17. Endothelial nitric oxide synthase phosphorylation in treadmill-running mice: role of vascular signalling kinases.
Zhang QJ; McMillin SL; Tanner JM; Palionyte M; Abel ED; Symons JD
J Physiol; 2009 Aug; 587(Pt 15):3911-20. PubMed ID: 19505983
[TBL] [Abstract][Full Text] [Related]
18. Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.
Lim HJ; Crowe P; Yang JL
J Cancer Res Clin Oncol; 2015 Apr; 141(4):671-89. PubMed ID: 25146530
[TBL] [Abstract][Full Text] [Related]
19. β Common receptor integrates the erythropoietin signaling in activation of endothelial nitric oxide synthase.
Su KH; Shyue SK; Kou YR; Ching LC; Chiang AN; Yu YB; Chen CY; Pan CC; Lee TS
J Cell Physiol; 2011 Dec; 226(12):3330-9. PubMed ID: 21321940
[TBL] [Abstract][Full Text] [Related]
20. Sirtuin 6 inhibits colon cancer progression by modulating PTEN/AKT signaling.
Tian J; Yuan L
Biomed Pharmacother; 2018 Oct; 106():109-116. PubMed ID: 29957460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
